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Background: Epidermal growth factor receptor (EGFR) gene mutations identify patients with non-small cell lung
cancer (NSCLC) who have a high likelihood of benefiting from treatment with anti-EGFR tyrosine kinase inhibitors.
Sanger sequencing is widely used for mutation detection but can be technically challenging, resulting in longer
turn-around-time, with limited sensitivity for low levels of mutations. This manuscript details the technical
performance verification studies and external clinical reproducibility studies of the cobas EGFR Mutation Test, a
rapid multiplex real-time PCR assay designed to detect 41 mutations in exons 18, 19, 20 and 21.
Methods: The assay’s limit of detection was determined using 25 formalin-fixed paraffin-embedded tissue
(FFPET)-derived and plasmid DNA blends. Assay performance for a panel of 201 specimens was compared against
Sanger sequencing with resolution of discordant specimens by quantitative massively parallel pyrosequencing
(MPP). Internal and external reproducibility was assessed using specimens tested in duplicate by different operators,
using different reagent lots, instruments and at different sites. The effects on the performance of the cobas EGFR
test of endogenous substances and nine therapeutic drugs were evaluated in ten FFPET specimens. Other tests
included an evaluation of the effects of necrosis, micro-organisms and homologous DNA sequences on assay
performance, and the inclusivity of the assay for less frequent mutations.
Results: A >95% hit rate was obtained in blends with >5% mutant alleles, as determined by MPP analysis, at a total
DNA input of 150 ng. The overall percent agreement between Sanger sequencing and the cobas test was 96.7%
(negative percent agreement 97.5%; positive percent agreement 95.8%). Assay repeatability was 98% when tested
with two operators, instruments, and reagent lots. In the external reproducibility study, the agreement was > 99%
across all sites, all operators and all reagent lots for 11/12 tumors tested. Test performance was not compromised
by endogenous substances, therapeutic drugs, necrosis up to 85%, and common micro-organisms. All of the
assessed less common mutations except one (exon 19 deletion mutation 2236_2248 > AGAC) were detected at a
similar DNA input level as that for the corresponding predominant mutation.
Conclusion: The cobas EGFR Mutation Test is a sensitive, accurate, rapid, and reproducible assay.
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Lung cancer has the highest incidence of all solid organ
cancers and is the most common cause of death from can-
cer worldwide, accounting for over 1.6 million new cases
annually and 1.38 million deaths [1]. Almost 85% of all lung
cancers are non-small cell lung cancer (NSCLC). The ob-
servation that the epidermal growth factor receptor (EGFR)
is over-expressed in most cases of NSCLC led to the devel-
opment of the specific anti-EGFR tyrosine kinase inhibitors
(TKIs) gefitinib and erlotinib as targeted therapeutic agents.
However, clinical trials with these agents revealed that in
most cases, responders harbored specific activating muta-
tions in exons 18–21 which collectively encode the kinase
domain of the EGFR gene [2-5]. The majority of mutations
that have been associated with sensitivity to gefitinib and
erlotinib are located in exon 19 (45%) and exon 21 (40–
45%), although ~5% are located in exon 18 and <1% in
exon 20 [6]. In addition, certain mutations in exon 20, such
as T790M, predict resistance to these TKIs [7].
The association between sensitizing mutations in the
EGFR gene and response to treatment has led to recom-
mendations by major oncology organizations that NSCLC
tumors should be tested for the presence of these muta-
tions before treatment [8-10]. Thus, from a practical
perspective, optimal care of patients will depend on inter-
actions between a patient’s pulmonologist and oncologist,
relying on information from the molecular pathology of
the tumor tissue [11]. In recognition of the need for accur-
ate testing, these organizations have started consolidating
guidelines for molecular testing in lung cancer to follow
standards for sensitivity, specificity, and time to results to
ensure quality of patient treatment [12].
As with other tumor types, diagnostic assays should be
optimized for use with formalin-fixed paraffin-embedded
tissue (FFPET) specimens, which continue to represent
the vast majority of NSCLC samples in clinical practice
today. Molecular testing in NSCLC poses particular chal-
lenges for the pathologist and clinician alike. In many
cases the amount of tumor tissue available for testing (e.g.
bronchial biopsy) is very limited and, given the growing
number of molecular and immunohistochemical studies
that are performed as part of the diagnostic workup, there
are competing diagnostic demands for the small amount
of available material. Thus, an optimal diagnostic test
should require a small amount of DNA. Furthermore,
many patients with metastatic NSCLC are often quite ill
and require prompt initiation of targeted therapy when in-
dicated, making a rapid molecular assay highly desirable.
The importance of using standardized techniques for
both extraction and molecular analysis was stressed by a re-
cently convened expert working group who discussed the
challenges of NSCLC diagnosis in the current era [11]. This
group recommended against using laboratory developed
tests, as such methods are subject to great inter- and intra-laboratory variability and do not always pass adequate qual-
ity control schemes that ensure reproducibility of results.
Instead, the group recommends, where possible, using cer-
tified diagnostic kits with prior laboratory validation.
We designed a highly sensitive, specific, reproducible
test that detects mutations in exons 18, 19, 20, and 21 in
tumor samples from patients with NSCLC to identify in-
dividuals who are most likely to respond to EGFR TKI
therapy using one 5-micron tissue section. Here, we
present the technical performance verification studies of
the cobas EGFR Mutation Test, including studies of the
analytic sensitivity, internal and external reproducibility,
minimal tumor content, interfering substances, effects of
necrosis, and cross-reactivity with other mutations.
Methods
Materials
FFPET specimens of NSCLC tumors were obtained from
US and European commercial vendors: Analytical
Biological Services Inc. (Wilmington, DE, USA), Asterand,
Inc. (Detroit, MI, USA), BioServe (Beltsville, MD, USA),
Conversant (Huntsville, AL, USA), Cureline Inc. (South
San Francisco, CA, USA), Cytomyx (Lexington, MA,
USA), Discovery Life Sciences, Inc. (Los Osos, CA, USA),
ILSBio, LLC (Chestertown, MD, USA), Indivumed
(Hamburg, Germany), OriGene (Rockville, MD, USA), and
ProteoGenex (Culver City, CA, USA). In addition, FFPET
specimens of NSCLC tumors were provided by Astellas
Pharma US, Inc. (Deerfield, IL, USA). All specimens were
aged between 3 and 10 years.
Human epidermal growth factor receptor (HER) plas-
mids: HER2, HER3, and HER4 were purchased from In-
tegrated DNA Technologies (San Diego, CA, USA).
K562, human genomic DNA, used as wild-type se-
quence, was obtained from the human lymphoma cell line
K562 (Promega, Madison WI; part number DD201X).
Ethics statement
Methods described below were not used in the diagnosis or
treatment of any patients. Patient consent forms were
obtained through the commercial vendor. RMS and the
principal investigators from the external reproducibility
study abided by the International Conference on Harmonisa-
tion Good Clinical Practice Guidelines and regulations of the
US Food and Drug Administration (FDA) in the conduct of
this study. Before the start of the study, the protocol and
other documents necessary for participating sites to perform
the study was submitted to an independent Institutional Re-
view Board (IRB) in accordance with FDA and local legal re-
quirements. IRB approval was obtained at each site.
cobas EGFR mutation test
The cobas EGFR Mutation Test (“cobas EGFR test”,
Roche Molecular Systems, Inc, Branchburg, NJ, USA) is
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specific polymerase chain reaction (AS-PCR) to detect 41
mutations in exons 18, 19, 20, and 21 in FFPET specimens
of human NSCLC. The test consists of two major steps: (1)
a manual DNA isolation step, and (2) PCR amplification
and detection of target DNA using complementary primer
pairs and oligonucleotide probes labeled with fluorescent
dyes (Figure 1). The test is designed to detect G719X
(G719A, G719C, and G719S) in exon 18; deletions and
complex mutations in exon 19; S768I, T790M, and inser-
tions in exon 20; and L858R in exon 21. The specific muta-
tions detected by the assay are detailed in Table 1. A
mutant control and a negative control are included in each
run to confirm the validity of the run. The test uses 150 ng
total input DNA, an amount which can typically be
extracted from a single 5 μm section of an FFPET speci-
men using the cobas DNA Sample Preparation Kit (Roche
Molecular Systems, Inc, Branchburg, NJ, USA), following
the standard package insert protocol [13]. Macrodissection
of the tissue section is only required if the estimated tumor
content is < 10% by pathological assessment. Mutation ana-
lysis is performed through real-time PCR analysis using the
cobas 4800 System (version 2.0), and the analysis of raw
data and reporting of results are fully automated. The
DNA isolation, amplification and detection, and result
reporting can be performed in less than 8 hours. Testing
for this study was conducted with cobas 4800 System Soft-
ware (version 2.0.0.1028). Analysis was performed with the
EGFR Analysis Package Software V.1.0Figure 1 cobas EGFR Mutation Test workflow. EGFR, epidermal growth
hematoxylin and eosin; PCR, polymerase chain reaction.Sanger sequencing
DNA from FFPET specimens using the same extraction
method as described for the cobas EGFR test were
extracted and amplified at Roche Molecular Systems,
and sent out for 2× bidirectional Sanger sequencing
(Sanger) by a Clinical Laboratory Improvement Amend-
ments (CLIA)-certified laboratory (SeqWright, Houston,
TX, USA) using a validated protocol.
Quantitative massively parallel pyrosequencing
NSCLC FFPET-derived DNA blends and specimens that
gave discordant cobas EGFR test and Sanger test results as
well as a randomly selected subset of concordant speci-
mens were tested using a quantitative massively parallel
pyrosequencing method (“MPP”, 454 GS Titanium, 454
Life Sciences, Branford, CT, USA) [14]. DNA was
extracted and amplified at Roche Molecular Systems prior
to being sent to a CLIA-certified laboratory (SeqWright,
Houston, TX, USA) to be sequenced using a validated
protocol for EGFR mutation detection. The analytical sen-
sitivity of MPP for EGFR mutations was validated to a
limit of detection of 1.25%.
Analytical sensitivity
The analytical sensitivity of the cobas EGFR test was
assessed using FFPET-derived DNA blends and plasmid
DNA blends. For the FFPET DNA blends, seventeen
NSCLC FFPET specimens were selected for their muta-
tion status (three positive for exon 19 deletions; threefactor receptor; FFPE, formalin-fixed paraffin-embedded; H&E,
Table 1 cobas EGFR mutation test coverage
Exon Mutations detected Mutation report call
18 G719A, G719C, G719S G719X
19 29 deletions Exon 19 deletion
20 T790M T790M
S768I S768I
5 insertions Exon 20 insertion
21 L858R (2 variants*) L858R
EGFR, epidermal growth factor receptor; PCR, polymerase chain reaction.
*2573 T > G; 2573_2574TG > GT.
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and T790M mutations; one positive for S768I and
G719C mutations; one positive for G719A mutation; one
positive for an exon 20 insertion mutation; and seven
EGFR wild-type specimens) as determined by Sanger se-
quencing. Specimen blends were prepared targeting ap-
proximately 10%, 5%, 2.5%, and 1.25% mutant DNA as
quantified by MPP pyrosequencing. Serial dilutions of
each specimen were prepared and eight replicates were
tested with three cobas EGFR test reagent lots, yielding
a total of 24 replicates per panel member.
Six plasmid constructs containing the most frequently
observed mutation for each mutation group detected by
the test were blended with K562 wild-type DNA such that
each sample contained a ~5% blend of mutant plasmid at
the copy number equivalent of 50 ng/PCR. Serial dilutions
of each specimen were prepared to make panels with five
members. DNA samples were diluted while leaving the
percent mutation constant. An additional panel member
containing 100% wild-type DNA was included to each
panel. Each of the six levels of the six plasmid DNA blend
specimens was tested with each of three unique cobas
EGFR test lots. Three dilutions were formulated for each
plasmid in each mutation group for each of the three re-
agent kit lots. Eight replicates of each of the three dilution
series was tested for each of the three kit lots, yielding a
total of seventy-two replicates per panel member.
Method correlation
Analytical performance of the cobas EGFR test was
compared against 2× bidirectional Sanger sequencing
using 201 FFPET human NSCLC specimens. Correlation
between the two methods was assessed by agreement
analysis, including positive percent agreement (PPA),
negative percent agreement (NPA), and overall percent
agreement (OPA). Specimens with invalid results on ei-
ther method were excluded from the correlation ana-
lysis. The cobas EGFR test results were considered
invalid if any or all of the mutation calls were reported
as invalid. Sanger sequencing results were considered in-
valid if any or all of the four exons failed to provide a
valid result for a specimen. Sanger sequencing resultswere considered invalid if any or all of the four exons
failed to provide a valid result for a specimen. Specimens
with discordant cobas EGFR test and Sanger sequencing
results and a randomly selected subset of specimens
with concordant results were subjected to MPP.
Repeatability/Reproducibility
The internal repeatability of the cobas EGFR test was eval-
uated using six NSCLC FFPET specimens: two EGFR
wild-type and four EGFR-mutation positive specimens
(one exon 19 deletion, one with G719X and S768I muta-
tions, one with L858R and T790M mutations, and one
with exon 20 insertion mutation). Testing was performed
in duplicate by two operators, using two different reagent
lots and two cobas z 480 analyzers over 4 days. Each oper-
ator performed one run per reagent lot per day for 4 days,
giving a total of 16 runs and 32 replicate results for each
of the six specimens.
The external reproducibility of the cobas EGFR test
across three clinical laboratories using three reagent
lots and two operators per site was evaluated using a
13-member panel of NSCLC specimens containing five
different deletions in exon 19 and exon 21 L858R in the
EGFR gene (Table 2). Operators performed blinded runs
(two replicates of each panel member/run), on five
nonconsecutive days, using a single instrument per site. A
total of 180 DNA replicate specimens were prepared for
each panel member, and each of the three sites performed
a total of 780 tests. All statistical analyses were performed
using SAS®/STAT® software. The sample identification
numbers of panel members were randomized using PROC
PLAN in SAS, and the order of panel members within
each run was randomized. Only valid tests from valid runs
were included in the statistical analyses.
The mutation status and percent mutant alleles of the
specimens chosen for the repeatability and reproducibil-
ity studies was determined using Sanger sequencing and
MPP, respectively, and tumor content was estimated for
each specimen by assessment from an external patholo-
gist. DNA was extracted and blended to create samples
containing levels of EGFR mutation above the limit of
detection for the cobas platform. The percentage of mu-
tant alleles in the blended samples was verified by MPP.
Potential interfering substances
The effects on the performance of the cobas EGFR test
from two endogenous substances (hemoglobin and triglyc-
erides) and nine therapeutic drugs that may be present
in human NSCLC specimens (albuterol, ipratropium,
fluticasone, ceftazidime, imipenem, piperacillin-tazobactam
, cilastatin sodium, povidone iodide, and lidocaine) were in-
vestigated with 10 NSCLC FFPET specimens. Specimens
were selected for mutation status based on Sanger and/or
MPP. Five specimens were EGFR mutation-positive and
Table 2 External reproducibility panel design
Panel member Mutation status
1 Wild Type
2 Exon 19 – deletion mutation #1 – LOD
(EX19_ 2235_2249del15 - 5% Mutation)
3 Exon 19 – deletion mutation #2 – LOD
(EX19_2236_2250del15 - 5% Mutation)
4 Exon 19 – deletion mutation #3 - LOD
(EX19_2239_2248 > C - 5% Mutation)
5 Exon 19 – deletion mutation #4 - LOD
(EX19_2240_2254del15 - 5% Mutation)
6 Exon 19 – deletion mutation #5 - LOD
(EX19_2240_2257del18 - 5% Mutation)
7 Exon 21 L858R mutation – LOD
(EX21_ 2573T > G = L858R - 5% Mutation)
8 Exon 19 – deletion mutation #1 – 2 × LOD
(EX19_ 2235_2249del15 - ≤10% Mutation)
9 Exon 19 – deletion mutation #2 – 2 × LOD
(EX19_2236_2250del15 - ≤10% Mutation)
10 Exon 19 – deletion mutation #3 – 2 × LOD
(EX19_2239_2248 > C - ≤10% Mutation)
11 Exon 19 – deletion mutation #4 – 2 × LOD
(EX19_2240_2254del15 - ≤10% Mutation)
12 Exon 19 – deletion mutation #5 – 2 × LOD
(EX19_2240_2257del18 - ≤10% Mutation)
13 Exon 21– L858R mutation – 2 × LOD
(EX21_ 2573T > G = L858R - ≤10% Mutation)
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and presence of each potential interferent. Each potential
interferent was spiked during the lysis step. Hemoglobin
and triglycerides were added to achieve 1× the upper limit
of normal concentration seen in common pathological
conditions (as defined by the Clinical and Laboratory
Standards Institute [CLSI] EP7-A2 Guideline; 2 g/L
hemoglobin and 37 mM triglycerides) [15]. The therapeutic
drugs were added to achieve a final concentration of 3× the
maximal plasma concentration (as defined by the CLSI
EP7-A2 Guideline) [15], if known. Povidone iodide was
tested as a 10% weight by volume solution; lidocaine was
tested at a concentration of 12 μg/mL, as recommended by
the CLSI EP7-A2 Guideline [15].
Effects of necrosis
The impact of tissue necrosis on the cobas EGFR test
detection of mutations was evaluated. Twenty NSCLC
FFPET specimens were tested in duplicate: ten speci-
mens covering a range of percent mutation from the
exon 19 deletion, S768I, L858R, G719X, and exon 20insertion mutation groups, and ten wild-type specimens.
Percent necrosis, as assessed by a pathologist, varied
from 0% to 60% for mutant specimens and from 5% to
85% for wild-type specimens.
Cross-reactivity
To confirm that other gene sequences homologous to the
targeted EGFR exons do not interfere with the perform-
ance of the cobas EGFR test, potential cross-reactivity was
assessed for three members of the ErbB family of receptor
tyrosine kinases (HER2, HER3, and HER4). The homolo-
gous sequences in HER2, HER3, and HER4 corresponding
to the probe-targeted portions of exons 18, 19, 20, and 21
in the EGFR gene were individually cloned into 12 plas-
mids (four exon regions per HER gene) and evaluated with
the cobas EGFR test. We also sought to determine if the
assay, which is designed to detect 29 deletions in exon 19
would also detect the rare exon 19 L747S point mutation,
using a plasmid containing this mutation. Ten NSCLC
FFPET specimens (four with EGFR mutations, six wild
type) were evaluated in the presence (spiked to a concen-
tration of 15,850 copies/PCR well, the equivalent of 50 ng
of genomic DNA) and absence of each of the HER plas-
mids as well as the plasmid containing the L747S muta-
tion. The plasmids were spiked into individual replicates
of each of the ten specimens after extraction; one replicate
of each of the 10 specimens was not spiked with plasmid
and was used as the control.
Genotype inclusivity
To assess the inclusivity of the assay for mutations in all
four key exons of EGFR (exons 18–21), the detection of
less common non-predominant EGFR mutations was
studied for each of the four exons (G719X point muta-
tions in exon 18, deletions in exon 19 deletions, inser-
tions in exon 20, and a two base pair mutation that
yields variant in the L858R mutation in exon 21). Plas-
mid constructs containing these less common mutations
were blended with wild-type DNA (K562). The initial
plasmid DNA input level was determined by the findings
from the analytical sensitivity study for the predominant
mutation (as detailed above). If the hit rate at this level
was too low, then the next highest DNA input level was
tested, with levels subsequently increased up a max-
imum of 50 ng/PCR. Each plasmid DNA blend sample
was tested with one test kit lot, and a total of 24 repli-
cates were tested per sample.
Microorganism exclusivity
Ten NSCLC FFPET specimens (five mutation positive,
five wild-type) were tested with two common respiratory
microorganisms (Haemophilus influenzae and Strepto-
coccus pneumoniae), Controls (normal substance level
which did not contain any added organism) were used
Table 4 Analytical sensitivity of plasmid DNA blends
EGFR Mutation Nucleic Acid
Sequence
Amount of DNA in 5%
copy equivalent (ng/25uL)
to achieve ≥95% “Mutation
Detected” Rate
(N = 72 replicates/plasmid)




Exon 20 S768I 2303 G > T 0.78






Exon 21 L858R 2573 T > G 0.78
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CFU/mL. A total of 30 test conditions were run.
Results
Analytical sensitivity
The analytical sensitivity of the cobas EGFR test for exon
19 deletion, L858R, S768I, T790M, G719X, and exon 20
insertion mutations was assessed using NSCLC FFPET-
derived DNA blends and six plasmid DNA blends. For the
FFPET-derived DNA blends the lowest percent mutation
level that was associated with ≥95% hit rate with 50 ng/
PCR reaction ranged from 1.3% to 5.6% (Table 3). For the
plasmid blends, the amount of DNA in 5% copy equiva-
lent to achieve ≥ 95% mutation detected rate ranged from
0.78 and 3.13 ng/PCR reaction (Table 4). Together, the
data show that the cobas EGFR test can detect the pre-
dominant mutation for each of the six mutation groups
when it is present as 5% mutant alleles.
Method correlation and test failure rate
Of the 201 specimens evaluated in the methods correl-
ation between the cobas EGFR test and Sanger sequen-
cing, 49 specimens gave invalid test results for one or both
methods produced an invalid result. Forty-eight specimens
were invalid by Sanger sequencing (23.8%). Six specimens
(3.0%) were invalid by cobas EGFR test using reagent lot 1
(5/6 of these specimens were also invalid by Sanger), and
five specimens (2.5%) were invalid using reagent lot 2 (4/5
specimens were also invalid for Sanger).
The comparison of the remaining 152 valid results is
shown in Table 5. The OPA between both cobas EGFR
test lots and Sanger sequencing was 96.7%, with five dis-
cordant specimens for each lot. All specimens yieldingTable 3 Analytical sensitivity of formalin-fixed paraffin-






Lowest % mutation in the
50 ng/PCR well input to
achieve ≥95% “mutation
detected” rate
(N = 24 replicates)
Exon 19 deletion 1 2235_2249del15 1.39
2 2236_2250del15 2.53
3 2238_2252del15 2.37
L858R 4 2573 T > G 3.96
5 2573 T > G 4.19
6 2573 T > G 4.33
7 2573 T > G 5.32
T790M 7 2369 C > T 2.04
S768I 8 2303 G > T 2.42
Exon 20 insertion 9 2310_2311insGGT 1.26
G719X 10 2156 G > C 2.46
8 2155 G > T 5.56discordant resultants with either reagent lot were further
analyzed by MPP. Discordant analysis results are listed
in Table 6. Sanger sequencing detected two mutation
calls (one G719A, one exon 19 deletion) that were not
confirmed by the cobas EGFR test or MPP. Two speci-
mens designated “mutation not detected” by Sanger
were detected by MPP (exon 19 deletion, exon 20 inser-
tion). Both lots of the cobas EGFR test called one speci-
men “mutation not detected” that was called as G719S
by MPP at 1.1% mutation, which is below the 5% limit
of detection of the cobas EGFR test. One specimen was
detected as an exon 19 deletion by cobas EGFR lot 2,
but not detected for both Sanger and cobas EGFR lot 1.
This specimen was detected as an exon 19 deletion at
3% mutation by MPP, which is below the limit of detec-
tion of the cobas EGFR test. Lastly, cobas EGFR test lot
1 detected one specimen with an exon 20 insertion. This
specimen was called “mutation not detected” by Sanger
sequencing, cobas EGFR test lot 2, and MPP.
Internal Repeatability/External Reproducibility
All runs from the internal repeatability analysis were
valid across all specimens, reagent lots, operators, and
instruments combined. A single replicate of one speci-
men gave an invalid result. The specimen was repeated
and the valid result replaced the invalid result, which
was excluded from data analysis. Initially six (6) false
calls out of 192 specimens were observed generating a
total percent accuracy of 96.9%. Two of the results were
resolved to confirm the observed result by the cobas
EGFR test. Three of the false calls were confirmed by
MPP; the L858R false call was not confirmed by MPP.
With two of the six false calls resolved the assay deliv-
ered 188 correct calls out of 192 specimens tested, or an
accuracy of 97.9%.
In the external reproducibility study, a total of 2,340
tests were performed on the 13 panel members in 90 valid
runs (see Table 2 for list of panel member. No invalid re-
sults were obtained. No false positive results were ob-
served, as all 180 replicates of wild-type specimens (95%
Table 5 Agreement analysis of cobas EGFR mutation test (per lot) versus sanger
Sanger Sanger
MD MND Total MD MND Total
cobas EGFR test Lot 1 MD 69 2 71 cobas EGFR test Lot 2 MD 69 2 71
MND 3 78 81 MND 3 78 81
Total 72 80 152 Total 72 80 152
Positive agreement = 95.8% (95% CI: 88.3 to 99.1%). Positive agreement = 95.8% (95% CI: 88.3 to 99.1%).
Negative agreement = 97.5% (95% CI: 91.3 to 99.7%). Negative agreement = 97.5% (95% CI: 91.3 to 99.7%).
Overall agreement = 96.7% (95% CI: 92.5 to 98.9%). Overall agreement = 96.7% (95% CI: 92.5 to 98.9%).
CI, confidence interval; MD, mutation detected; MND, mutation not detected.
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the exon 19 and exon 21 panel members with 5% muta-
tion, one panel member (EX19_2240_2257del18) had a hit
rate below 95% (62.8%, -95% CI [55.3–69.9%]),This may
have been due to poor DNA quality in the tumor block
used. Although this panel member appeared to have a
lower than 95% hit rate, the Ctr SD and CV(%) for this
panel member were within the range of the remaining
panel members. For all exon 19 and exon 21 panel mem-
bers with ≤10% mutation had 99.4% (95% CI [96.9–100])
agreement. Overall the external reproducibility study
showed little variation in the cobas EGFR test perform-
ance at multiple clinical sites (Table 7).
Interference/Cross-Reactivity/Effects of necrosis
No interference was observed for hemoglobin and tri-
glycerides at CLSI-recommended test concentrations of
2 g/L and 37 mM for any of the 10 FFPET specimens.
No interference by therapeutic drugs was observed on
the performance of the cobas EGFR test.
No interference from necrotic tissue was observed
when evaluating the performance of the cobas EGFR
test. Results for all specimens were concordant with
Sanger sequencing and MPP results. Thus, levels of ne-
crosis up to 85% did not affect test performance.
Results for the ten FFPET specimens tested under the
13 conditions using the cobas EGFR test matched the
expected results for HER2/3/4 cross-reactivity. One spe-
cimen that was spiked with the HER4 exon 21 analog
plasmid initially produced a result of “Mutation Not
Detected”, but yielded the correct call upon retesting.
The plasmid with the exon 19 L747S mutation yieldedTable 6 Discordant specimen resolution by MPP




4 MND Exon 19 deletion
5 Ex 20 Insertion Exon 20 insertion
6 Ex 20 Insertion MNDan exon 19 deletion call in all specimens that did not
already contain an exon 19 deletion, confirming cross-
reactivity between the L747S mutation and the cobas
EGFR test. The BLAST (Basic Local Alignment Search
Tool) results demonstrated that the primers and probes
in the cobas EGFR test are unlikely to cross-hybridize
with sequences other than the target sequence. Analo-
gous sequences to the targeted EGFR exons from the
HER2, HER3, and HER4 genes did not interfere with the
performance of the cobas EGFR test.
Genotype inclusivity
Results are presented in Additional file 1: Table S1. All of
the assessed less common mutations except one (exon 19
deletion mutation 2236_2248 > AGAC) were detected at a
similar DNA input level as that for the corresponding pre-
dominant mutation. The exon 19 deletion mutation
2236_2248 > AGAC was not consistently detected at any
DNA input level.
Microorganism exclusivity
Neither Haemophilus influenzae nor Streptococcus
pneumoniae had any effect on the performance of the
cobas EGFR test (data not shown).
Discussion
There is a pressing clinical need for a well-validated EGFR
testing method with optimal analytical performance, turn-
around time, using the least amount of difficult-to-obtain
patient specimens. There is also a clear need for guidelines
surrounding method performance characteristics. Here,
we present results on seven out of 25 analytical validationSanger MPP
G719A MND
G719S G719S (1.1% mutation)
Exon 19 deletion MND
MND Exon 19 deletion (3.0% mutation)
MND Exon 20 insertion (13.7% mutation)
MND MND
Table 7 External reproducibility across reagent lots, operators, instruments, and testing days
Panel Member Number of Valid Tests Agreement (N) Agreement % (95% CI)a
Wild Type 180 180 100 (98.0, 100.0)
EX19_ 2235_2249del15 - 5% Mutation 180 180 100 (98.0, 100.0)
EX19_2236_2250del15 - 5% Mutation 180 180 100 (98.0, 100.0)
EX19_2239_2248 > C - 5% Mutation 180 180 100 (98.0, 100.0)
EX19_2240_2254del15 - 5% Mutation 180 180 100 (98.0, 100.0)
EX19_2240_2257del18 - 5% Mutation 180 113 62.8 (55.3, 69.9)
EX21_ 2573T > G = L858R - 5% Mutation 180 180 100 (98.0, 100.0)
EX19_ 2235_2249del15 - ≤10% Mutation 180 180 100 (98.0, 100.0)
EX19_2236_2250del15 - ≤10% Mutation 180 180 100 (98.0, 100.0)
EX19_2239_2248 > C - ≤10% Mutation 180 180 100 (98.0, 100.0)
EX19_2240_2254del15 - ≤10% Mutation 180 180 100 (98.0, 100.0)
EX19_2240_2257del18 - ≤10% Mutation 180 179 99.4 (96.9, 100.0)
EX21_ 2573T > G = L858R - ≤10% Mutation 180 180 100 (98.0, 100.0)
Note: Results were in agreement when a Mutant Type panel member had a valid result of Mutation Detected or when Wild Type panel member had a valid result
of Mutation Not Detected.
a 95% CI = 95% exact binomial confidence interval.
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as well as external reproducibility study of the test run at
multiple clinical sites. It is important to note that valid-
ation studies were performed on plasmid specimens as
well as FFPET specimens, allowing an accurate under-
standing the of test performance in typical clinical speci-
mens. Performance of the test in alternative specimen
types is currently being conducted.
One commonly used method for interrogating muta-
tions in the EGFR gene is Sanger sequencing. Sanger se-
quencing is highly variable based on lab-validated
protocols. In some cases, Sanger sequencing takes up to
600 ng of DNA to interrogate all 4 exons in the EGFR
gene [16]. Particularly in the field of NSCLC, where pa-
tient samples are difficult to obtain and testing (molecu-
lar and immunohistochemical) is being prioritized for
treatment decisions, the efficient use of limited specimen
is of great importance. The cobas EGFR test detects 41
mutations in exons 18, 19, 20, and 21 and uses 150ng of
total DNA input. The studies described in this manu-
script indicate that the cobas EGFR test is able to detect
mutations in EGFR exons 18, 19, 20, and 21 at ≥5% mu-
tation level using only 50 ng of DNA per reaction well,
an amount that typically can be extracted from a single
5 μm curl. The cobas EGFR test was able to detect mu-
tations that were confirmed by MPP but not detected by
Sanger sequencing. The increased sensitivity of the
cobas EGFR test is consistent with previous studies of
other PCR-based mutation assays [17-19]. The sensitivity
of Sanger sequencing may be increased to some extent
by taking measures to enrich for tumor tissue, such as
macrodissection or laser microcapture. However, these
measures require extra time and effort on the part of thepathologist, and in some cases require the use of special-
ized equipment. By contrast, the cobas EGFR test does
not require macrodissection unless the estimated tumor
content in the specimen is below 10%.
To confirm the greater sensitivity of the cobas EGFR
test compared to Sanger, a third comparator method
was used, MPP. To eliminate any sequencing bias, both
Sanger sequencing and MPP were performed by an ex-
ternal laboratory that was blinded to the results of the
cobas EGFR test. In the four of six cases, MPP con-
firmed the cobas EGFR test result. The Sanger sequen-
cing provided two false positive mutation calls and two
false negative mutation calls, which in the clinical setting
would have resulted in two patients who would be un-
likely to respond to treatment, receiving treatment, and
patients who would benefit from treatment being denied
the intervention. Occasional false positive results with
Sanger sequencing have been observed in other studies
[17,20,21], perhaps reflecting some inherent subjectivity
in the interpretation of Sanger sequencing results. Such
subjectivity is eliminated from the cobas EGFR test, as
the analysis and reporting of results are fully automated.
Low invalid rates expedite time to result and avoiding
the unnecessary use of additional specimens for retesting.
Of interest, the low invalid rates were observed despite the
samples being between 3 and 10 years old. The studies
also show that the cobas EGFR test is more robust than
Sanger sequencing with a lower invalid test rate (3% for
cobas vs 23.8% for Sanger). Very few reported method
comparison studies have compared invalid test rates be-
tween different assay methods. However, we have previ-
ously demonstrated very low invalid test rates for other
mutation assays on this platform [17,20].
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turnaround time (~1 day for 24 samples; 1 kit), which is
considerably shorter than for Sanger sequencing (~5
days). The slower turnaround time for Sanger sequen-
cing and its higher invalid test rate, which potentially re-
sults in the need for reanalysis, could lead to important
delays in patients receiving appropriate treatment for
NSCLC. This is an important concern as the majority of
patients present with advanced, disseminated disease
[22]. This rapid and sensitive method enables efficient
testing of limited tissue specimens, where patient sam-
ples are difficult to obtain and molecular testing must be
prioritized for treatment algorithms.
As part of the validation of the cobas EGFR test we ex-
amined both internal repeatability and external reprodu-
cibility. In the internal repeatability analysis, the cobas
EGFR test had high accuracy (98%) across all specimens,
reagent lots, operators, and instruments combined. High
reproducibility was observed in the external reproduci-
bility analysis although one sample was observed to con-
tribute a disproportionate amount to the variability
observed. This sample had 5% mutation; however, ana-
lysis at ≤10% improved reproducibility to >97%. An
evaluation of EGFR testing in 15 French centers showed
low concordance between sites, ranging from median
kappa values of 0.47 (0.45-0.49) for Exon 19 and 21,
underpinning the critical need to set standards for EGFR
mutation testing [8,23]. The external reproducibility
study is targeted for submission alongside results from
clinical trial entitled, “Phase III Study (Tarceva®) vs
Chemotherapy to Treat Advanced Non-Small Cell Lung
Cancer (NSCLC) in Patients With Mutations in the TK
Domain of EGFR” (clinical trial # NCT00446225). The
clinical utility of the cobas EGFR test was assessed
through a retrospective analysis of specimens from the
EURTAC trial (clinical trial # NCT00446225). Though
there has been consideration of the use of next gener-
ation sequencing in routine clinical diagnostics, for the
accurate selection of patient therapy, method of testing
for EGFR mutations should be well validated both clinic-
ally and analytically.
Our study also demonstrated that a variety of potential
interfering substances – including endogenous substances,
common medications, and respiratory microorganisms –
had no significant effect on the assay’s analytic perform-
ance. A thorough understanding of the specimen attri-
butes that could affect a molecular assay are a key
component of test optimization and validation.
Conclusions
The analytic studies presented here show that the cobas
EGFR test is a sensitive, accurate, rapid, and reprodu-
cible assay for EGFR mutations that allows clinicians to
identify those patients with advanced NSCLC who havea high likelihood of benefiting from treatment with anti-
EGFR TKI therapies.
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